Key Developments: Synta Pharmaceuticals Corp (SNTA.OQ)

SNTA.OQ on NASDAQ Stock Exchange Global Market

6.09USD
1 Aug 2013
Price Change (% chg)

$-0.62 (-9.24%)
Prev Close
$6.71
Open
$6.64
Day's High
$6.90
Day's Low
$6.04
Volume
617,019
Avg. Vol
463,669
52-wk High
$11.77
52-wk Low
$3.77

Search Stocks

Latest Key Developments (Source: Significant Developments)

Synta Pharmaceuticals Corp Announces ENCHANT-1 Breast Cancer Results Support Transition to Second Stage of Trial
Monday, 29 Jul 2013 07:00am EDT 

Synta Pharmaceuticals Corp announced that preliminary results from the ENCHANT-1 clinical trial, which evaluates ganetespib monotherapy in patients with newly diagnosed locally advanced or metastatic HER2 positive or triple-negative breast cancer (TNBC), achieved the prespecified criteria for advancing to the second stage of the trial. Of the initial five HER2-positive patients enrolled in the study, two achieved objective tumor response and two achieved stable disease (SD) within the three cycles of treatment on study (12 weeks). Of the initial ten TNBC patients enrolled and evaluable for response, two achieved objective tumor response and three achieved SD following treatment with ganetespib monotherapy. Metabolic response was also assessed in the study, by comparing baseline and week 3 PET scans. Of the five HER2-positive patients, four achieved metabolic responses. Of the 13 TNBC patients with post-baseline PET scans, six achieved metabolic response.  Full Article

Synta Pharmaceuticals Corp Announces Positive Overall Survival Results From GALAXY-1 Phase 2b/3 Trial Of Ganetespib In Second-Line Non-Small Cell Lung Cancer
Monday, 3 Jun 2013 07:34am EDT 

Synta Pharmaceuticals Corp announced results from an interim survival analysis of the GALAXY-1 trial, a global, randomized, multi-center Phase 2b/3 study designed to evaluate the efficacy and safety of the Company's lead drug candidate, the Hsp90 inhibitor ganetespib, as second-line treatment for patients with advanced non-small cell lung adenocarcinoma. The results show that the combination of ganetespib (G) plus docetaxel (D) improves overall survival (OS) and progression-free-survival (PFS) compared to docetaxel alone. The results also show that these improvements are enhanced in the pre-specified patient population that was selected last year for evaluation in the ongoing GALAXY-2 Phase 3 trial. The GALAXY-1 trial consists of two enrollment stages: a primary enrollment stage, which completed in November 2012 with 252 adenocarcinoma patients, and an extension enrollment stage for those patients with certain biomarker disease characteristics, which completed enrollment in May 2013 with an additional 70 patients. Interim analyses of overall survival from the primary adenocarcinoma enrollment stage were specified six and twelve months from the last patient enrolled. Data lock for the six-month follow-up analysis was May 15, 2013. As specified in the clinical trial protocol, analysis of the biomarker-defined patient populations will occur upon maturity of data from both the primary and extension enrollment stages, expected later this year.  Full Article

Synta Pharmaceuticals Corp Announces $60 Million Registered Direct Common Stock Offering
Thursday, 13 Dec 2012 07:30am EST 

Synta Pharmaceuticals Corp announced that it has entered into common stock purchase agreements with members of Board of Directors and various institutional investors for the sale of 7,000,000 shares of common stock in an issuer directed, registered direct offering. Shares were priced at $8.60, the consolidated closing bid price as of December 12, 2012, for gross proceeds of approximately $60 million. No underwriter or placement agent was used in this transaction. The offering is expected to close on or about December 18, 2012, subject to satisfaction of customary closing conditions. Net proceeds from the offering will be used to fund Synta's operations, including, research and development, clinical trials, manufacturing, intellectual property protection and enforcement, and working capital, and for other general corporate purposes.  Full Article

Synta Pharmaceuticals Corp Announces Proposed Registered Direct Offering Of Common Stock
Wednesday, 12 Dec 2012 04:05pm EST 

Synta Pharmaceuticals Corp announced that it has commenced an issuer directed, registered direct offering of its common stock. Shares will be priced at closing market value, and Synta expects to raise gross proceeds of approximately $40 million to $50 million. No underwriter or placement agent will be used in this transaction. Members of Synta`s Board of Directors are expected to participate in the offering. Net proceeds from the offering will be used to fund Synta's operations, including, research and development, clinical trials, manufacturing, intellectual property protection and enforcement, and working capital, and for other general corporate purposes.  Full Article

Synta Pharmaceuticals Corp Updates Results from Phase 2b/3 GALAXY Trial Show Promising Improvement in Survival from Addition of Ganetespib to Docetaxel in Second-Line Non-Small Cell Lung Cancer
Saturday, 29 Sep 2012 04:00am EDT 

Synta Pharmaceuticals Corp announced results from an interim analysis of the Phase 2b portion of the GALAXY trial, a global, randomized, multi-center Phase 2b/3 study designed to evaluate the efficacy and safety of the Company’s lead Hsp90 inhibitor, ganetespib, as second-line treatment for advanced non-small cell lung cancer (NSCLC). The results showed good tolerability for the combination of ganetespib (G) and docetaxel (D), as well as meaningful improvements in overall survival (OS) in adenocarcinoma patients receiving docetaxel plus ganetespib compared to those receiving docetaxel alone. The GALAXY trial is based on a two-stage, operationally adaptive design. The first-stage, randomized, open-label, 240-patient Phase 2b portion of the trial is enrolling Stage IIIB/IV NSCLC patients who have progressed following one prior line of therapy, and is designed to identify the patient population, defined by biomarker or other disease characteristic, for advancement into the Phase 3 portion of the trial. An interim analysis was planned for when approximately 80% of the target 240 adenocarcinoma patients had been enrolled. A total of 187 patients were enrolled at the time of analysis, of which 172 patients had been entered into the clinical database at the time of data cutoff.  Full Article

Synta Pharmaceuticals Corp. Announces $25.8 Million Registered Direct Offering Of Common Stock
Thursday, 26 Jul 2012 07:30am EDT 

Synta Pharmaceuticals Corp. announced that it has entered into common stock subscription agreements with members of its Board of Directors for the sale of 3,976,702 shares of its common stock in a registered direct offering at a price of $6.49 per share, for gross proceeds of approximately $25.8 million. The shares were offered directly to the purchasers without a placement agent, underwriter, broker or dealer. The sale and issuance of the shares is expected to close on or about July 27, 2012. The net proceeds from the offering will be used to fund Synta’s operations, including advancement of Synta’s lead drug candidate, ganetespib, other research and development, clinical trials, manufacturing, intellectual property protection and enforcement, and working capital, and for other general corporate purposes.  Full Article

Synta Pharmaceuticals Corp. Announces Results Demonstrating Potent Ganetespib Activity Across Broad Range Of Crizotinib-Resistant ALK+ NSCLC Models At The European Lung Cancer Conference
Wednesday, 18 Apr 2012 08:30am EDT 

Synta Pharmaceuticals Corp. announced preclinical results at the third European Lung Cancer Conference in Geneva, Switzerland that show ganetespib, a potent inhibitor of heat shock protein 90 (Hsp90), equally inhibits growth of both crizotinib-sensitive and -resistant cancer cells driven by the EML4-ALK fusion protein regardless of ALK mutation status. Additional results from mouse ALK+ NSCLC xenograft models demonstrated anticancer activity with combined administration of ganetespib and crizotinib that was significantly higher than when either drug was administered alone. Direct ALK inhibitors such as crizotinib act by targeting a particular site on the ALK protein and reducing its ability to drive cancer cell growth and proliferation. Secondary mutations in the ALK protein generate resistance to these ALK inhibitors. Both crizotinib and second-generation ALK inhibitors have shown mixed results against acquired resistance in ALK+ NSCLC, including reduced potency against certain secondary ALK mutations and near complete lack of activity against other ALK mutations. In contrast, ganetespib, which acts by inhibiting Hsp90, a necessary chaperone for ALK activity, is equally potent against crizotinib-sensitive cells as well as all crizotinib-resistant cells with secondary ALK mutations. In this study, ganetespib displayed greater potency than other targeted agents and chemotherapeutics utilized in ALK+ NSCLC, including ALK inhibitors and pemetrexed.  Full Article

Syntel Pharmaceuticals Corp. Sells Additional 1,050,000 Shares Of Common Stock
Monday, 6 Feb 2012 04:10pm EST 

Synta Pharmaceuticals Corp. announced the completion of the sale of 1,050,000 additional shares of its common stock pursuant to the full exercise of the over-allotment option granted to the underwriters of its previously announced public offering. After underwriting discounts and commissions and estimated offering expenses payable by Synta, aggregate net proceeds from the offering were approximately $32.9 million. Jefferies & Company, Inc. acted as the sole book-running manager for the offering, and Canaccord Genuity Inc. and Roth Capital Partners, LLC acted as co-managers for the offering.  Full Article

Synta Pharmaceuticals Corp. Closes Public Offering Of Common Stock
Wednesday, 11 Jan 2012 04:01pm EST 

Synta Pharmaceuticals Corp. announced the closing of its underwritten public offering of 7,000,000 shares of common stock at a public offering price of $4.40 per share. Net proceeds to Synta are approximately $28.6 million, after deducting the underwriting discounts and commissions and estimated offering expenses payable by Synta. Synta has granted the underwriters a thirty (30) day option to purchase up to 1,050,000 additional shares to cover over-allotments, if any. Jefferies & Company, Inc. acted as the sole book-running manager for the offering, and Canaccord Genuity Inc. and Roth Capital Partners, LLC acted as co-managers for the offering.  Full Article

Synta Pharmaceuticals Corp. Prices Public Offering Of Common Stock
Friday, 6 Jan 2012 09:02am EST 

Synta Pharmaceuticals Corp. announced that it has priced an underwritten public offering of 7,000,000 shares of its common stock at a price to the public of $4.40 per share. Net proceeds to Synta are expected to be approximately $28.6 million, after deducting the underwriting discounts and commissions and estimated offering expenses payable by Synta. The offering is expected to close on or about January 11, 2012, subject to satisfaction of customary closing conditions. Synta has granted the underwriters a 30 day option to purchase up to 1,050,000 additional shares to cover over-allotments, if any. Jefferies & Company, Inc. is acting as the sole book-running manager for the offering, and Canaccord Genuity Inc. and Roth Capital Partners, LLC are acting as co-managers for the offering.  Full Article

Synta Pharma shares soar after co says to expand breast cancer study

- Synta Pharmaceuticals Corp shares soared as much as 47 percent in heavy trading after the company said preliminary results from a mid-stage study of its drug ganetespib in breast cancer patients supported an expansion of the study.

Search Stocks